|
|
|
|
| LEADER |
02045nam a2200277 u 4500 |
| 001 |
EB001872103 |
| 003 |
EBX01000000000000001035474 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 020 |
|
|
|a 9781473119024
|
| 245 |
0 |
0 |
|a Key therapeutic topics-medicines management options for local implementation
|h Elektronische Ressource
|b interim process statement
|c National Institute for Health and Clincal Excellence
|
| 260 |
|
|
|a London
|b National Institute for Health and Clinical Excellence (NICE)
|c 2013, 31 January 2013
|
| 300 |
|
|
|a 1 PDF file (16 pages)
|
| 653 |
|
|
|a United Kingdom
|
| 653 |
|
|
|a Drug Therapy / standards
|
| 653 |
|
|
|a State Medicine
|
| 653 |
|
|
|a Practice Guidelines as Topic
|
| 653 |
|
|
|a Quality Assurance, Health Care / standards
|
| 710 |
2 |
|
|a National Institute for Health and Clinical Excellence (Great Britain)
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Process and methods guides
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK425818
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This interim process statement has been produced by the National Institute for Health and Clinical Excellence (NICE) to guide the development of the QIPP key therapeutics document, 'Key therapeutic topics - Medicines management options for local implementation'. It provides an overview of the key process and principles, and describes all stages of the development of the QIPP key therapeutics document. These procedures are designed to ensure that a robust, quality-assured document is developed for the NHS in an open, transparent and timely way, with appropriate input from key groups. This interim process statement uses the NICE Implementation Support Tool process as an overarching guide to the principles of its development. This interim process statement will be superseded when the final process guide is issued later in 2013, following engagement and discussions with key groups
|